Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. Capricor ( ) is a biotechnology company developing transformative therapeutics for diseases.

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

In case you missed it: Capricor shared third-quarter 2025 financial results and a corporate update highlighting continue...
11/11/2025

In case you missed it: Capricor shared third-quarter 2025 financial results and a corporate update highlighting continued progress across our programs.
Catch the replay of our webcast here: https://bit.ly/4nqoZtX

On Veterans Day, we pause to honor the courage, sacrifice and service of our nation’s veterans, and the families who sta...
11/11/2025

On Veterans Day, we pause to honor the courage, sacrifice and service of our nation’s veterans, and the families who stand beside them. Your commitment inspires us to pursue life-changing science with purpose every day.
Thank you for your service.

We just released our third quarter 2025 financial results and provided a corporate update. Click here to read the releas...
11/10/2025

We just released our third quarter 2025 financial results and provided a corporate update. Click here to read the release: https://bit.ly/43X4fD9

We are pleased to announce the publication of new data in the international peer-reviewed journal, Biomedicines describi...
11/03/2025

We are pleased to announce the publication of new data in the international peer-reviewed journal, Biomedicines describing the mechanism of action and potency assay for our investigational cell therapy, Deramiocel.

The publication details how Deramiocel, which is composed of cardiosphere-derived cells (CDCs), has demonstrated potent anti-fibrotic and immunomodulatory effects.

Read the publication https://bit.ly/3WBHn8l.

$CAPR

Capricor will report Q3 financial results after the market close Monday, November 10, 2025, and will host a conference c...
10/31/2025

Capricor will report Q3 financial results after the market close Monday, November 10, 2025, and will host a conference call and webcast at 4:30 p.m. ET that same day.
To register for the webcast: https://bit.ly/4nqoZtX

Capricor Therapeutics has been named to TIME’s “America’s Growth Leaders 2026” list, recognizing companies across the U....
10/24/2025

Capricor Therapeutics has been named to TIME’s “America’s Growth Leaders 2026” list, recognizing companies across the U.S. with sustained growth and performance.
Coming in at #23 of 500, this recognition highlights the dedication of our incredible team and our unwavering commitment to the patients and families who inspire our work to support those living with Duchenne muscular dystrophy.
To our team and the DMD patient community: thank you for supporting us as we continue to advance meaningful therapies and make an impact where it matters most.Full list is here: http://bit.ly/4o7apIY

Capricor was pleased to participate in the Maxim Group 2025 Growth Summit this morning.Our Chief Financial Officer, AJ B...
10/22/2025

Capricor was pleased to participate in the Maxim Group 2025 Growth Summit this morning.
Our Chief Financial Officer, AJ Bergmann, joined the session: Unlocking Value in Late-Stage/Commercial Rare Disease. This important discussion explored how companies are advancing innovation, improving patient outcomes, and creating value across the rare disease landscape.
We’re proud to have our leadership contributing to this meaningful dialogue. Learn more: http://bit.ly/3WDfSvj

We’re proud to share that our CEO, Dr. Linda Marbán will be speaking at the STAT Summit taking place this week in Boston...
10/15/2025

We’re proud to share that our CEO, Dr. Linda Marbán will be speaking at the STAT Summit taking place this week in Boston. This premier event brings together industry leaders who are defining the next era of medicine from AI-driven discovery to breakthroughs in cell therapy. To see the full agenda, click here https://bit.ly/42AYmLy

Capricor is pleased to provide a regulatory update on our Deramiocel program for Duchenne muscular dystrophy (DMD) follo...
09/25/2025

Capricor is pleased to provide a regulatory update on our Deramiocel program for Duchenne muscular dystrophy (DMD) following our recent Type A meeting with the FDA. We will also be hosting a conference call today at 8:30 AM ET — http://bit.ly/4mD3Axx

Capricor is excited to be featured at the Exosome-Based Therapeutics Development Summit taking place this week in Boston...
09/23/2025

Capricor is excited to be featured at the Exosome-Based Therapeutics Development Summit taking place this week in Boston, where we will highlight the progress of our exosome platform and its potential to deliver next-generation therapeutics. Learn more: http://bit.ly/3IBaYv7

Today, on World Duchenne Awareness Day, Capricor stands with patients and families living with DMD. This rare genetic di...
09/07/2025

Today, on World Duchenne Awareness Day, Capricor stands with patients and families living with DMD. This rare genetic disorder affects thousands worldwide, and together, through awareness and research, we share hope for brighter tomorrows. Capricor remains committed to advancing treatments and supporting this community.

We will be featured in a fireside chat today at the Cantor Fitzgerald Global Healthcare Conference scheduled for 10:55 A...
09/05/2025

We will be featured in a fireside chat today at the Cantor Fitzgerald Global Healthcare Conference scheduled for 10:55 AM ET (7:55 AM PT). Register here for the live webcast: http://bit.ly/46jIkaZ

Address

10865 Road To The Cure
San Diego, CA
92121

Website

Alerts

Be the first to know and let us send you an email when Capricor Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Capricor Therapeutics, Inc.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram